Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00502112 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00502112 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 13 participants.
The verdict
NCT00502112, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study is a phase I, open-label, single-arm, dose escalation trial to determine the safety and activity of lenalidomide combined with lintuzumab in patients with MDS. Small groups of 3-6 patients will be treated with pre-specified doses of lenalidomide and lintuzumab and will receive 3-week cycles of combination therapy.
Interventions
- DRUG lenalidomide
- DRUG lintuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00502112
The ClinicalTrials.gov registry entry for NCT00502112 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lenalidomide is the first listed.
NCT00502112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00502112 about?
NCT00502112 is a clinical study titled "A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)". This study is a phase I, open-label, single-arm, dose escalation trial to determine the safety and activity of lenalidomide combined with lintuzumab in patients with MDS. Small groups of 3-6 patients will be treated with pre-specified doses of lenalidomide and lintuzumab and will receive 3-week cycl...
What is the current status of trial NCT00502112?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2008-03. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00502112?
The interventions under investigation include: lenalidomide (DRUG), lintuzumab (DRUG).
Who is sponsoring clinical trial NCT00502112?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.